Open Source · MIT License

Evidence-Based Enhancement, Open Source

Browse compounds scored by real research from PubMed and Semantic Scholar. Build stacks. Track cycles. Free forever.

107

compounds

10747

studies indexed

100%

free, forever

Research-Backed

Evidence scores computed from real peer-reviewed studies on PubMed and Semantic Scholar.

Stack Builder

Combine compounds into goal-driven protocols. Check interactions. Fork and share community stacks.

Cycle Tracker

Log doses, bloodwork, weight, and subjective markers daily. Visualize progress over time.

Open Source

Community-driven. No paywalls, no ads. Every compound, every study, always free.

Highest Evidence Scores

Top compounds by research coverage

View all

Tirzepatide

81
fat loss
Rx

Dual GLP-1/GIP receptor agonist; GIP agonism sensitizes adipocytes and augments incretin effect beyond GLP-1 alone

Evidence

Strong evidence

Safety

Safety unknown

185 studiesn/a
10mg · Once weekly subcutaneousView

Creatine Monohydrate

78
supplement

Increases intracellular phosphocreatine, enhancing ATP resynthesis during high-intensity activity

Evidence

Strong evidence

Safety

Safety unknown

395 studiesn/a
5g · dailyView

Retatrutide

78
fat loss
Research Only

Triple GLP-1/GIP/glucagon receptor agonist; adds hepatic fat mobilization and increased energy expenditure to GLP-1/GIP incretin effects

Evidence

Strong evidence

Safety

Safety unknown

122 studiesn/a
8mg · Once weekly subcutaneous (trial doses)View

Semaglutide

78
fat loss
Rx

GLP-1 receptor agonist: delays gastric emptying, suppresses appetite via hypothalamic signaling, stimulates glucose-dependent insulin secretion

Evidence

Strong evidence

Safety

Safety unknown

495 studiesn/a
1mg · Once weekly (injection); once daily (oral Rybelsus)View

Survodutide

77
fat loss
Research Only

Dual GLP-1/glucagon receptor agonist; adds hepatic fat mobilization and increased energy expenditure to GLP-1 satiety effects

Evidence

Strong evidence

Safety

Safety unknown

148 studiesn/a
4.8mg · Once weekly subcutaneous (trial doses)View

HGH

76
hormonal
Rx

Binds GH receptor on hepatocytes → IGF-1 production; directly stimulates lipolysis in adipose; promotes nitrogen retention and tissue repair via IGF-1/mTOR/PI3K

Evidence

Strong evidence

Safety

Safety unknown

291 studiesn/a
2IU · Once daily subcutaneous injection (typically evening or pre-sleep)View

How Evidence Scoring Works

Every compound gets a score from 0–100 based on six factors computed from indexed research. No manual curation. No opinion. Pure data.

Study Count

More studies mean a stronger evidence signal.

Study Quality

RCTs and systematic reviews weighted over case reports.

Sample Size

Larger cohorts reduce noise in the signal.

Consistency

Aligned results across independent research groups.

Replication

Multiple independent replications required for high scores.

Recency

Recent research weighted more heavily than older studies.

Start Exploring

Browse the compound database, build a stack, or contribute to the open-source project.